Cost Plus Drugs Plans Expansion Into Custom-Made Rare Disease Medicines
Start here
Cost Plus Drugs, known for its generics business, plans to begin producing custom-made medicines for rare diseases. The company says its plant can switch quickly between small production batches, allowing it to manufacture experimental treatments for individual patients or small groups. The move would take the operation beyond low-cost generics into small-batch, personalized production, a segment conventional manufacturers often serve poorly because of limited demand. Where the plan now stands, what conditions or treatments will be targeted first, pricing, and regulatory timing all remain open questions.
Written by a model from the reports · updated 5 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- STATSTAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more
Cost Plus Drugs plans to expand from its generics business into custom-made medicines for rare diseases. The company says its plant can quickly switch among small batches, enabling experimental treatments for individuals or very small patient groups. Meanwhile, Sandoz's plant in Kundl, Austria, Europe's only fully integrated penicillin facility, faces an uncertain future as China supplies the same antibiotics and active ingredients to the European market at lower cost.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 22:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.